[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Tumor microenvironment,Cytokines,Regulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Koscso<\/b>, Z. Ao, C. Passaro, N. Shah, N. Ly, P. Timpug, B. A. Aksoy, D. Sun, D. Li, K.-L. Sheahan, V. Young, T. Ross, B. Primack, M. Langley, J. Tchaicha, D. K. Sethi, J. ter Meulen, M. Ols; <br\/>Obsidian Therapeutics, Inc., Cambridge, MA","CSlideId":"","ControlKey":"bf81202f-f7f6-4f6b-8c82-d32304470605","ControlNumber":"9556","DisclosureBlock":"<b>&nbsp;B. Koscso, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>Z. Ao, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>C. Passaro, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>SanaBiotechnology<\/b> Stock. <br><b>N. Shah, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>N. Ly, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>P. Timpug, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment. <br><b>B. A. Aksoy, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>MOMA Therapeutics<\/b> Stock Option. <br><b>Beam Therapeutics, BioNTech SE, CRISPR, Ginkgo Bioworks, Immuneering, Intellia Therapeutics, Invitae, Iovance Biotherapeutics, Johnson & Johnson, Mirati Therapeutics, Prime Medicine<\/b> Stock. <br><b>Relay Therapeutics, Revolution Medicines, Vertex Pharmaceuticals, Verve Therapeutics<\/b> Stock. <br><b>D. Sun, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>Pfizer<\/b> Stock. <br><b>D. Li, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>Biogen<\/b> Stock. <br><b>K. Sheahan, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>Arbor Biotechnology<\/b> Stock Option. <br><b>V. Young, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>T. Ross, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option. <br><b>B. Primack, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>M. Langley, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>J. Tchaicha, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment. <br><b>D. K. Sethi, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>J. ter Meulen, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment. <br><b>M. Ols, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Patent. <br><b>Biogen Idec<\/b> Stock.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10559","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB065","PresenterBiography":null,"PresenterDisplayName":"Balazs Koscso, PhD","PresenterKey":"82f2635a-82b0-422b-8d74-3952434b9399","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB065. <b>Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors<\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b>Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors<\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,T lymphocytes,Leukemias: chronic myelogenous,Graft-vs-host-desease,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Batatinha<\/b>, G. M. Niemiro, N. Pena, G. Hoskin, P. Mylabathula, F. Baker, T. Zuniga, K. Smith, D. Diak, M. Seckeler, E. Katsanis, R. Simpson; <br\/>University of Arizona, Tucson, AZ","CSlideId":"","ControlKey":"7f3d3baa-0038-468f-a467-e6e669be69f2","ControlNumber":"9879","DisclosureBlock":"&nbsp;<b>H. Batatinha, <\/b> None..<br><b>G. M. Niemiro, <\/b> None..<br><b>N. Pena, <\/b> None..<br><b>G. Hoskin, <\/b> None..<br><b>P. Mylabathula, <\/b> None..<br><b>F. Baker, <\/b> None..<br><b>T. Zuniga, <\/b> None..<br><b>K. Smith, <\/b> None..<br><b>D. Diak, <\/b> None..<br><b>M. Seckeler, <\/b> None..<br><b>E. Katsanis, <\/b> None..<br><b>R. Simpson, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10560","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB066","PresenterBiography":null,"PresenterDisplayName":"Helena Angelica Batatinha","PresenterKey":"3fe92bec-5eec-45a0-a703-e8d090804b62","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB066. Acute systemic beta-adrenergic receptor activation to improve graft composition and outcomes in hematopoietic stem cell transplantation","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Acute systemic beta-adrenergic receptor activation to improve graft composition and outcomes in hematopoietic stem cell transplantation","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Adoptive immunotherapy,T lymphocytes,Tumor infiltrating lymphocytes,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Weinberg<\/b><sup>1<\/sup>, B. Curti<sup>1<\/sup>, R. Montler<sup>2<\/sup>, C. Thalhofer<sup>2<\/sup>, E. Ballinger<sup>2<\/sup>, J. Cross<sup>2<\/sup>, E. Tran<sup>1<\/sup>, N. Sanjuan<sup>1<\/sup>, M. Taylor<sup>1<\/sup>, C. Fountain<sup>1<\/sup>, R. Payne<sup>1<\/sup>, J. Cardia<sup>3<\/sup>, N. Morris<sup>2<\/sup>; <br\/><sup>1<\/sup>Providence Cancer Institute, Portland, OR, <sup>2<\/sup>Agonox, Inc, Portland, OR, <sup>3<\/sup>Phio Pharmaceutical, Marlborough, MA","CSlideId":"","ControlKey":"3540cbdc-8315-4ae0-8c57-d9a051064d4e","ControlNumber":"10247","DisclosureBlock":"<b>&nbsp;A. Weinberg, <\/b> <br><b>Agonox, Inc.<\/b> Employment, Stock.<br><b>B. Curti, <\/b> None.&nbsp;<br><b>R. Montler, <\/b> <br><b>Agonox, Inc.<\/b> Employment, Stock, Stock Option. <br><b>C. Thalhofer, <\/b> <br><b>Agonox, Inc<\/b> Employment, Stock Option. <br><b>E. Ballinger, <\/b> <br><b>Agonox, Inc<\/b> Employment, Stock Option. <br><b>J. Cross, <\/b> <br><b>Agonox, Inc<\/b> Employment, Stock Option. <br><b>E. Tran, <\/b> <br><b>AstraZeneca<\/b> Employment.<br><b>N. Sanjuan, <\/b> None..<br><b>M. Taylor, <\/b> None..<br><b>C. Fountain, <\/b> None..<br><b>R. Payne, <\/b> None..<br><b>J. Cardia, <\/b> None.&nbsp;<br><b>N. Morris, <\/b> <br><b>Agony, Inc<\/b> Employment, Stock.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10561","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB067","PresenterBiography":null,"PresenterDisplayName":"Andrew Weinberg","PresenterKey":"e9509186-707d-4612-9a6c-b3fbcd28dadf","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB067. Tumor-reactive CD8 TIL with an exhausted phenotype can be expanded and regress human tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tumor-reactive CD8 TIL with an exhausted phenotype can be expanded and regress human tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Immunotherapy,CAR T cells,Solid tumors,Regulatory T cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. M. R. Ferreira<\/b>, R. W. Cochrane, R. A. Robino, B. Granger, E. Allen, V. Gudivada, A. A. de Cubas, S. Berto; <br\/>The Medical University of South Carolina (MUSC), Charleston, SC","CSlideId":"","ControlKey":"49aefd76-9aa5-4679-8a92-c8bbcb6c03fd","ControlNumber":"10705","DisclosureBlock":"<b>&nbsp;L. M. R. Ferreira, <\/b> <br><b>Patent filed<\/b> Patent.<br><b>R. W. Cochrane, <\/b> None..<br><b>R. A. Robino, <\/b> None..<br><b>B. Granger, <\/b> None..<br><b>E. Allen, <\/b> None..<br><b>V. Gudivada, <\/b> None..<br><b>A. A. de Cubas, <\/b> None..<br><b>S. Berto, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10562","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB068","PresenterBiography":null,"PresenterDisplayName":"Leonardo Ferreira, PhD","PresenterKey":"dcab1428-ece4-405b-a01f-5fc4eef72ee6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB068. Repurposing chimeric antigen receptor regulatory T cells for treating cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Repurposing chimeric antigen receptor regulatory T cells for treating cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Chimeric antigen receptor,Colorectal adenocarcinoma,Natural killer cells,Adoptive cell therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. Torchiaro, M. Cortese, A. D'Andrea, C. Petti, <b>E. Medico<\/b>; <br\/>Candiolo Cancer Institute, FPO IRCCS, Candiolo, Italy","CSlideId":"","ControlKey":"b87efba2-3247-44d8-91ad-77a6db66bb74","ControlNumber":"10798","DisclosureBlock":"&nbsp;<b>E. Torchiaro, <\/b> None..<br><b>M. Cortese, <\/b> None..<br><b>A. D'Andrea, <\/b> None..<br><b>C. Petti, <\/b> None..<br><b>E. Medico, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10563","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB069","PresenterBiography":null,"PresenterDisplayName":"Enzo Medico, MD, PhD","PresenterKey":"ce9a67bf-01d4-4e22-b288-b412fd2bb4ed","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB069. Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Chimeric antigen receptor,Exhaustion,Mesothelin,Spheroids,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Steele<\/b>, T. Tan, J. Yokoyama, A. Wang, T. Crowl, J. Hammer, J. Chen, K. Haworth, H. Moffett, A. Foster, M. Lajoie, S. Boyken, R. Amin; <br\/>Outpace Bio, Inc., Seattle, WA","CSlideId":"","ControlKey":"7e44e5f0-042e-42ea-bbb3-74bfdca81caf","ControlNumber":"9637","DisclosureBlock":"<b>&nbsp;M. Steele, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>T. Tan, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>J. Yokoyama, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>A. Wang, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>T. Crowl, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>J. Hammer, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>J. Chen, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>K. Haworth, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock Option. <br><b>H. Moffett, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock, Stock Option, Patent. <br><b>A. Foster, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock, Stock Option, Patent. <br><b>M. Lajoie, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Fiduciary Officer, Stock, Stock Option, Patent. <br><b>S. Boyken, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Fiduciary Officer, Stock, Stock Option, Patent. <br><b>R. Amin, <\/b> <br><b>Outpace Bio, Inc.<\/b> Employment, Stock, Stock Option, Patent.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10564","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB070","PresenterBiography":null,"PresenterDisplayName":"Maria Steele","PresenterKey":"b63489d3-e012-420b-9def-be967824befa","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB070. <i>In vitro <\/i>modeling of antigen-driven exhaustion in human CAR T cells","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<i>In vitro <\/i>modeling of antigen-driven exhaustion in human CAR T cells","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"CAR T cells,PD-L1,Solid tumors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Qie<\/b>, E. Garavito, M. Ulloa Navas, T. Hundal, A. Quinones-Hinojosa, H. Qin, y. luo; <br\/>Mayo Clinic  Florida, Jacksonville, FL","CSlideId":"","ControlKey":"651e1916-b33b-487d-bb72-c823f0349d24","ControlNumber":"10425","DisclosureBlock":"&nbsp;<b>Y. Qie, <\/b> None..<br><b>E. Garavito, <\/b> None..<br><b>M. Ulloa Navas, <\/b> None..<br><b>T. Hundal, <\/b> None..<br><b>A. Quinones-Hinojosa, <\/b> None..<br><b>H. Qin, <\/b> None..<br><b>Y. luo, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10565","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB071","PresenterBiography":null,"PresenterDisplayName":"Yan Luo, BMBCh;PhD","PresenterKey":"1aa7292d-a9b6-4e91-a868-e384d5390bad","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB071. Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Natural killer cells,Cytokines,Immuno-oncology,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Burga<\/b>, G. Kulkarni, Z. Ao, D. K. Sethi, J. ter Meulen, M. Ols; <br\/>Obsidian Therapeutics, Inc., Cambridge, MA","CSlideId":"","ControlKey":"1c058ead-187a-4f21-9e9c-35ff0137ac4d","ControlNumber":"10452","DisclosureBlock":"<b>&nbsp;R. Burga, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>G. Kulkarni, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>Z. Ao, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>D. K. Sethi, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>J. ter Meulen, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel. <br><b>M. Ols, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock Option, Travel.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10566","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB072","PresenterBiography":null,"PresenterDisplayName":"Rachel Burga, PhD","PresenterKey":"b5f47afc-4c97-4275-94b5-fb3c14f02826","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB072. Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Adoptive cell therapy,Tumor heterogeneity,Neoantigens,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Wolf<\/b><sup>1<\/sup>, V. Anastasopoulou<sup>2<\/sup>, K. Drousch<sup>2<\/sup>, M. Diehl<sup>1<\/sup>, B. Engels<sup>1<\/sup>, P. Yew<sup>1<\/sup>, K. Kiyotani<sup>3<\/sup>, Y. Nakamura<sup>3<\/sup>, K. Schreiber<sup>1<\/sup>, H. Schreiber<sup>1<\/sup>, M. Leisegang<sup>2<\/sup>; <br\/><sup>1<\/sup>University of Chicago, Chicago, IL, <sup>2<\/sup>Charité - Universitätsmedizin Berlin, Berlin, Germany, <sup>3<\/sup>Japanese Foundation for Cancer Research, Tokyo, Japan","CSlideId":"","ControlKey":"771a3a06-168e-4532-90e0-2a1c90324301","ControlNumber":"10524","DisclosureBlock":"&nbsp;<b>S. Wolf, <\/b> None..<br><b>V. Anastasopoulou, <\/b> None..<br><b>K. Drousch, <\/b> None..<br><b>M. Diehl, <\/b> None.&nbsp;<br><b>B. Engels, <\/b> <br><b>Novartis<\/b> Stock, Other, Past employment and personal fees. <br><b>Miltenyi Biotec<\/b> Employment.<br><b>P. Yew, <\/b> None.&nbsp;<br><b>K. Kiyotani, <\/b> <br><b>Cancer Precision Medicine Inc<\/b> Other, Scientific advisor and personal fees. <br><b>Y. Nakamura, <\/b> <br><b>OncoTherapy Science Inc<\/b> Stock, Other, Scientific advisor and personal fees.<br><b>K. Schreiber, <\/b> None..<br><b>H. Schreiber, <\/b> None..<br><b>M. Leisegang, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10567","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB073","PresenterBiography":null,"PresenterDisplayName":"Steven Wolf","PresenterKey":"6a8afd79-4310-487d-b034-84c03d7f32a1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB073. Adoptive transfer of one CD4TCR and one CD8TCR targeting autochthonous neoantigens are essential and sufficient for eradication of naturally heterogeneous solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Adoptive transfer of one CD4TCR and one CD8TCR targeting autochthonous neoantigens are essential and sufficient for eradication of naturally heterogeneous solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-01 Adoptive cell therapy,,"},{"Key":"Keywords","Value":"Adoptive cell therapy,CD19,CAR T cells,Immuno-oncology,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. Gov<\/b>, J. Yu, M. Qubain, S. L. Pompura, S. D. Allen, M. A. Christopher, J. Wiezorek; <br\/>Appia Bio, Culver City, CA","CSlideId":"","ControlKey":"184679d7-d697-458c-9446-507dd5519d97","ControlNumber":"10738","DisclosureBlock":"<b>&nbsp;L. Gov, <\/b> <br><b>Appia Bio<\/b> Employment, Stock, Patent. <br><b>J. Yu, <\/b> <br><b>Appia Bio<\/b> Employment, Stock, Patent. <br><b>M. Qubain, <\/b> <br><b>Appia Bio<\/b> Employment, Stock. <br><b>S. L. Pompura, <\/b> <br><b>Appia Bio<\/b> Employment, Stock Option. <br><b>S. D. Allen, <\/b> <br><b>Appia Bio<\/b> Employment, Stock, Patent. <br><b>M. A. Christopher, <\/b> <br><b>Appia Bio<\/b> Independent Contractor, Stock Option, Patent. <br><b>J. Wiezorek, <\/b> <br><b>Appia Bio<\/b> Employment, Stock.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10568","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB074","PresenterBiography":null,"PresenterDisplayName":"Lanny Gov","PresenterKey":"8525efb3-cb1f-49f3-9376-43dd824a53c6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB074. Preclinical development of API-192: An engineered CAR-NKT allogeneic cell therapy targeting CD19 and CD20 for the treatment of B-cell malignancies","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preclinical development of API-192: An engineered CAR-NKT allogeneic cell therapy targeting CD19 and CD20 for the treatment of B-cell malignancies","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-02 Combination immunotherapies,,"},{"Key":"Keywords","Value":"CAR T cells,Small molecule drugs,Combination therapy,Tumor antigen,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. R. E. Ranoa<\/b><sup>1<\/sup>, Y. Kang<sup>1<\/sup>, J. Drnevich<sup>1<\/sup>, G. Rendon<sup>1<\/sup>, C. J. Fields<sup>1<\/sup>, K. Bailey<sup>2<\/sup>, E. J. Roy<sup>1<\/sup>, T. M. Fan<sup>1<\/sup>, D. M. Kranz<sup>1<\/sup>, P. J. Hergenrother<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Illinois at Urbana-Champaign, Urbana, IL, <sup>2<\/sup>Alnylam Pharmaceuticals, Inc., Cambridge, MA","CSlideId":"","ControlKey":"c69e86b4-d2f4-4631-a62b-1e5a702fe433","ControlNumber":"10248","DisclosureBlock":"&nbsp;<b>D. R. E. Ranoa, <\/b> None..<br><b>Y. Kang, <\/b> None..<br><b>J. Drnevich, <\/b> None..<br><b>G. Rendon, <\/b> None..<br><b>C. J. Fields, <\/b> None..<br><b>K. Bailey, <\/b> None..<br><b>E. J. Roy, <\/b> None..<br><b>T. M. Fan, <\/b> None..<br><b>D. M. Kranz, <\/b> None..<br><b>P. J. Hergenrother, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10569","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB075","PresenterBiography":null,"PresenterDisplayName":"Diana Ranoa, PhD","PresenterKey":"e0b3558d-ae9d-48d8-b8ef-af2a11806273","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB075. Small molecule procaspase activating compound 1 (PAC-1) enhances CAR-T immunotherapy for solid tumors in syngeneic murine models","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Small molecule procaspase activating compound 1 (PAC-1) enhances CAR-T immunotherapy for solid tumors in syngeneic murine models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-02 Combination immunotherapies,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Antibody,Aging,Antitumor effect,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Kudo-Saito<\/b><sup>1<\/sup>, H. Imazeki<sup>1<\/sup>, H. Shoji<sup>2<\/sup>, N. Boku<sup>2<\/sup>; <br\/><sup>1<\/sup>Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan, <sup>2<\/sup>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan","CSlideId":"","ControlKey":"a5f18386-8f63-4698-8bd5-a603fe739a4c","ControlNumber":"9520","DisclosureBlock":"<b>&nbsp;C. Kudo-Saito, <\/b> <br><b>Ono Pharmaceutical<\/b> Other, Honoraria. <br><b>H. Imazeki, <\/b> <br><b>Ono Pharmaceutical<\/b> Honoraria. <br><b>H. Shoji, <\/b> <br><b>Ono Pharmaceutical<\/b> Grant\/Contract, Other, Honoraria. <br><b>Takeda Pharmaceutical<\/b> Grant\/Contract. <br><b>N. Boku, <\/b> <br><b>Ono Pharmaceutical<\/b> Grant\/Contract, Other, Honoraria. <br><b>Takeda Pharmaceutical<\/b> Grant\/Contract. <br><b>Eli Lilly<\/b> Other, Honoraria. <br><b>Bristol-Myers Squibb<\/b> Other, Honoraria. <br><b>Taiho<\/b> Other, Honoraria. <br><b>Daiichi-Sankyo<\/b> Other, Honoraria.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10570","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB076","PresenterBiography":null,"PresenterDisplayName":"Chie Kudo-Saito, PhD","PresenterKey":"0eb2a31d-3df5-49cf-a340-383f8ceca8d0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB076. Targeting an aging-related molecule overcomes resistance to anti-PD1 treatment of cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting an aging-related molecule overcomes resistance to anti-PD1 treatment of cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-02 Combination immunotherapies,,"},{"Key":"Keywords","Value":"Combination studies,CSF-1R,KRAS,NSCLC,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Zhang<\/b>, B. Shen, S. Liu, C. Dai, H. Ying, F. Guo, Z. Zhu, W. Shi, M. Tu, J. Wang, J. Zhang, M. Liu, Q. Zhang, Z. Chen; <br\/>Abbisko Therapeutics Co., Ltd., Shanghai, China","CSlideId":"","ControlKey":"a2eff4a7-c2af-4194-9f49-31463268c6a1","ControlNumber":"9865","DisclosureBlock":"&nbsp;<b>N. Zhang, <\/b> None..<br><b>B. Shen, <\/b> None..<br><b>S. Liu, <\/b> None..<br><b>C. Dai, <\/b> None..<br><b>H. Ying, <\/b> None..<br><b>F. Guo, <\/b> None..<br><b>Z. Zhu, <\/b> None..<br><b>W. Shi, <\/b> None..<br><b>M. Tu, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>M. Liu, <\/b> None..<br><b>Q. Zhang, <\/b> None..<br><b>Z. Chen, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10571","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB077","PresenterBiography":null,"PresenterDisplayName":"Nannan Zhang, PhD","PresenterKey":"7f13e728-32d8-4c0e-af86-ec105ac02592","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB077. CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRAS<sup>G12C<\/sup> inhibitors in preclinical non-small cell lung cancer mouse models","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRAS<sup>G12C<\/sup> inhibitors in preclinical non-small cell lung cancer mouse models","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-03 Immune checkpoints,,"},{"Key":"Keywords","Value":"Immune checkpoint,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Saha<\/b><sup>1<\/sup>, A. S. Shavkunov<sup>1<\/sup>, S. Singh<sup>1<\/sup>, A. J. Salmon<sup>1<\/sup>, S. Keshari<sup>1<\/sup>, Q. Miao<sup>1<\/sup>, B. T. Edelson<sup>2<\/sup>, C. Yee<sup>1<\/sup>, K. Chen<sup>1<\/sup>, M. Gubin<sup>1<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Washington University School of Medicine, St. Louis, MO","CSlideId":"","ControlKey":"13ea9b49-e042-4582-ad7c-63a31131a002","ControlNumber":"10850","DisclosureBlock":"&nbsp;<b>A. Saha, <\/b> None..<br><b>A. S. Shavkunov, <\/b> None..<br><b>S. Singh, <\/b> None..<br><b>A. J. Salmon, <\/b> None..<br><b>S. Keshari, <\/b> None..<br><b>Q. Miao, <\/b> None..<br><b>B. T. Edelson, <\/b> None..<br><b>C. Yee, <\/b> None..<br><b>K. Chen, <\/b> None..<br><b>M. Gubin, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10573","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB079","PresenterBiography":null,"PresenterDisplayName":"Akata Saha, PhD","PresenterKey":"1ae0df46-9547-45dd-afc6-8b713cf73b77","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB079. Cell-specific deletion of Bhlhe40 reveals distinct mechanisms underlying anti-PD-1 and anti-CTLA-4<b><\/b><b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cell-specific deletion of Bhlhe40 reveals distinct mechanisms underlying anti-PD-1 and anti-CTLA-4<b><\/b><b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-03 Immune checkpoints,,"},{"Key":"Keywords","Value":"Immune checkpoint,Screening,CRISPR,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T. Michels<\/b>, V. Volpin, C. Amerhauser, C. Tschulik, L. Majunke, A. Weglarz, K. Baritz, K. Sudan, S. Bak-Kiss, A. Huth, C. Strobl, A. Turqueti-Neves, N. Khandelwal; <br\/>iOmx Therapeutics AG, Martinsried\/Munich, Germany","CSlideId":"","ControlKey":"a3cee351-788d-4e3d-9083-b5158ea1c5dc","ControlNumber":"10649","DisclosureBlock":"<b>&nbsp;T. Michels, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>V. Volpin, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>C. Amerhauser, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>C. Tschulik, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>L. Majunke, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>A. Weglarz, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>K. Baritz, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>K. Sudan, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>S. Bak-Kiss, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>A. Huth, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>C. Strobl, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>A. Turqueti-Neves, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment. <br><b>N. Khandelwal, <\/b> <br><b>iOmx Therapeutics AG<\/b> Employment, Stock.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10574","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB080","PresenterBiography":null,"PresenterDisplayName":"Tillmann Michels, PhD","PresenterKey":"191b46e4-173b-4379-b182-5fe67b8e3df9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB080. iOTarg screening platform reveals novel mechanisms of colorectal cancer evasion from antigen-specific tumor cell killing by T cells<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"iOTarg screening platform reveals novel mechanisms of colorectal cancer evasion from antigen-specific tumor cell killing by T cells<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-04 Immune mechanisms invoked by other therapies including chemotherapy,,"},{"Key":"Keywords","Value":"Lymphoma: non-Hodgkin's lymphoma,Telomeres,TERT,Immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. Yu, Y. Liang, P. Swiderski, L. Kwak, <b>M. Kortylewski<\/b>; <br\/>City of Hope National Medical Center, Duarte, CA","CSlideId":"","ControlKey":"7b6ce64a-a159-4002-928b-a3f706e44352","ControlNumber":"10847","DisclosureBlock":"&nbsp;<b>C. Yu, <\/b> None..<br><b>Y. Liang, <\/b> None.&nbsp;<br><b>P. Swiderski, <\/b> <br><b>Scopus Biopharma<\/b> Stock, Patent.<br><b>L. Kwak, <\/b> None.&nbsp;<br><b>M. Kortylewski, <\/b> <br><b>Scopus Biopharma<\/b> Stock, Other, Scientific Advisory Board member. <br><b>Duet Therapeutics<\/b> Grant\/Contract, Other, Scientific Advisory Board member.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10575","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB081","PresenterBiography":null,"PresenterDisplayName":"Marcin Kortylewski, PhD","PresenterKey":"76fdb15f-4e46-47b3-90f9-f279de2b9f9c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB081. Novel targeted oligonucleotide-based telomere disruptor for immunotherapy of diffuse large B-cell lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Novel targeted oligonucleotide-based telomere disruptor for immunotherapy of diffuse large B-cell lymphoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-04 Immune mechanisms invoked by other therapies including chemotherapy,,"},{"Key":"Keywords","Value":"Breast cancer,Chemotherapy,Immuno-oncology,Immunogenic cell death,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. K. Bullock<\/b>, T. Hasaka, E. Days, J. Bauer, A. Richmond; <br\/>Vanderbilt University, Nashville, TN","CSlideId":"","ControlKey":"27a1a116-77ea-450e-b7e8-3a2f8d6e9ccc","ControlNumber":"10837","DisclosureBlock":"&nbsp;<b>K. K. Bullock, <\/b> None..<br><b>T. Hasaka, <\/b> None..<br><b>E. Days, <\/b> None..<br><b>J. Bauer, <\/b> None..<br><b>A. Richmond, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10576","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB082","PresenterBiography":null,"PresenterDisplayName":"Kennady Bullock, BA","PresenterKey":"1196163d-49bd-4d40-9ca4-ab245cb9fc53","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB082. A high-throughput immune-oncology screen identifies immunostimulatory properties of low dose chemotherapy in triple negative breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A high-throughput immune-oncology screen identifies immunostimulatory properties of low dose chemotherapy in triple negative breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-04 Immune mechanisms invoked by other therapies including chemotherapy,,"},{"Key":"Keywords","Value":"Immunogenic cell death,Esophageal cancer,PD-1,Antibody-drug conjugate (ADC),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>X.-F. Tian<\/b><sup>1<\/sup>, F. Chen<sup>2<\/sup>, X.-R. Xue<sup>1<\/sup>, Y. Yang<sup>3<\/sup>, P. Guo<sup>1<\/sup>; <br\/><sup>1<\/sup>Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China, <sup>2<\/sup>Molecular Science and Biomedicine Laboratory (MBL), Hunan University, Hunan, China, <sup>3<\/sup>Department of Thoracic Radiotherapy Zhejiang Cancer Hospital, Hangzhou, China","CSlideId":"","ControlKey":"14758f0b-eccb-492f-b946-f87927689540","ControlNumber":"10338","DisclosureBlock":"&nbsp;<b>X. Tian, <\/b> None..<br><b>F. Chen, <\/b> None..<br><b>X. Xue, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>P. Guo, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10577","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB083","PresenterBiography":null,"PresenterDisplayName":"Xue-Fei Tian","PresenterKey":"8665a9b2-974f-49cb-ab73-71b03fa2a8f7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB083. Near-infrared light-triggered tumor pyroptosis potentiates PD-1 immunotherapy in esophageal cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Near-infrared light-triggered tumor pyroptosis potentiates PD-1 immunotherapy in esophageal cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++IM01-05 Immune mechanisms invoked by radiation therapy,,"},{"Key":"Keywords","Value":"Radiation therapy,Immunotherapy,Stem-like T cells,tumor-draining lymph node,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Shen<sup>1<\/sup>, E. Connolly<sup>2<\/sup>, M. Aiello<sup>1<\/sup>, C. Zhou<sup>1<\/sup>, H. Song<sup>1<\/sup>, T. Clark<sup>1<\/sup>, P. Tippitak<sup>1<\/sup>, G. B. Lesinski<sup>3<\/sup>, C. Paulos<sup>4<\/sup>, N. Schmitt<sup>5<\/sup>, <b>Z. S. Buchwald<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, <sup>2<\/sup>Bioinformatics Graduate Program, Georgia Institute of Technology, Atlanta, GA, <sup>3<\/sup>Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, <sup>4<\/sup>Department of Surgery and Winship Cancer Institute, Emory University, Atlanta, GA, <sup>5<\/sup>Department of Otolaryngology and Winship Cancer Institute, Emory University, Atlanta, GA","CSlideId":"","ControlKey":"c20e4767-ece1-412b-b799-66d5fe193d43","ControlNumber":"10702","DisclosureBlock":"&nbsp;<b>Y. Shen, <\/b> None..<br><b>E. Connolly, <\/b> None..<br><b>M. Aiello, <\/b> None..<br><b>C. Zhou, <\/b> None..<br><b>H. Song, <\/b> None..<br><b>T. Clark, <\/b> None..<br><b>P. Tippitak, <\/b> None..<br><b>G. B. Lesinski, <\/b> None..<br><b>C. Paulos, <\/b> None..<br><b>N. Schmitt, <\/b> None..<br><b>Z. S. Buchwald, <\/b> None.","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"10578","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB084","PresenterBiography":null,"PresenterDisplayName":"Zachary Buchwald, MD, PhD","PresenterKey":"30a19058-04d3-4339-91e3-1d3863e72a4f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB084. Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  1:30PM","SessionId":"601","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Immunology 1","ShowChatLink":"false","Start":"4\/7\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node","Topics":null,"cSlideId":""}]